Location [1]
Protein [2]
Transcription factor E2-alpha
Synonyms [1]
TCF-3, ITF1, VDIR, AGM8, p75, E47, E2A, bHLHb21

Transcription factor 3 (TCF3; also known as E2A) is a gene that encodes a protein that functions in transcriptional activation by binding to regulatory E-box sequences on target genes. The protein also plays an important role in lymphopoiesis and T lymphocyte development. Fusions, missense mutations, nonsense mutations, silent mutations, frameshift deletions and insertions, and in-frame deletions are observed in cancers such as endometrial cancer, intestinal cancer, and skin cancer.

TCF3 is altered in 0.22% of all cancers with high grade ovarian serous adenocarcinoma, breast invasive ductal carcinoma, prostate adenocarcinoma, and undifferentiated pleomorphic sarcoma having the greatest prevalence of alterations [3].

TCF3 GENIE Cases - Top Diseases

The most common alterations in TCF3 are TCF3 Loss (0.17%) and TCF3 Amplification (0.03%) [3].

TCF3 GENIE Cases - Top Alterations

Significance of TCF3 in Diseases

Acute Lymphoblastic Leukemia +

Acute Myeloid Leukemia +

Myelodysplastic Syndromes +

Chronic Myeloid Leukemia +

Hodgkin Lymphoma +

Acute Biphenotypic Leukemia +

Burkitt Lymphoma +

Multiple Myeloma +

Non-Hodgkin Lymphoma +

Mantle Cell Lymphoma +

Anaplastic Large Cell Lymphoma +

Chronic Lymphocytic Leukemia +

Acute Leukemia +

Follicular Lymphoma +

Lymphoma +

Marginal Zone Lymphoma +

Juvenile Myelomonocytic Leukemia +

Myelofibrosis +

Myeloproliferative Neoplasm +

Prolymphocytic Leukemia +

Acute Undifferentiated Leukemia +

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma +

Chronic Myelomonocytic Leukemia +

Lymphoblastic Lymphoma +

Diffuse Large B-Cell Lymphoma +

Lymphoplasmacytic Lymphoma +

Plasma Cell Leukemia +

Secondary Acute Myeloid Leukemia +

T-Cell Lymphoblastic Leukemia/Lymphoma +

Therapy-Related Myelodysplastic Syndrome +

Acute Erythroid Leukemia +

Acute Megakaryoblastic Leukemia +

B-Cell Acute Lymphoblastic Leukemia +

B-Cell Prolymphocytic Leukemia +

Burkitt Leukemia +

Small Lymphocytic Lymphoma +

T-Cell Prolymphocytic Leukemia +

Malignant Solid Tumor +

Acute Leukemia Of Ambiguous Lineage +

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome +

Adult T-Cell Leukemia/Lymphoma +

Aplastic Anemia +

Leukemia +

Mature T-Cell And NK-Cell Lymphoma/Leukemia +

Mature T-Cell And NK-Cell Neoplasm +

Mature T-Cell And NK-Cell Non-Hodgkin Lymphoma +

Myelodysplastic Syndrome With Excess Blasts-2 +

Myelodysplastic/Myeloproliferative Neoplasm +

Myeloid Sarcoma +

Natural Killer Cell Lymphoblastic Leukemia/Lymphoma +

Peripheral T-Cell Lymphoma +

Plasma Cell Neoplasm +

Refractory Anemia +

Refractory Anemia With Excess Blasts +

Refractory Anemia With Excess Blasts-1 +

T-Cell And NK-Cell Neoplasm +

Therapy-Related Acute Myeloid Leukemia +

Therapy-Related Chronic Myelomonocytic Leukemia +


1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta

2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.

3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.

4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.